Canada markets closed

Vertex Pharmaceuticals Incorporated (0QZU.L)

LSE - LSE Delayed Price. Currency in USD
Add to watchlist
476.25+2.34 (+0.49%)
At close: 07:14PM BST
Currency in USD

Valuation Measures4

Market Cap (intraday) N/A
Enterprise Value N/A
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)N/A
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA N/A

Trading Information

Stock Price History

Beta (5Y Monthly) 0.41
52-Week Change 337.54%
S&P500 52-Week Change 322.55%
52 Week High 3477.36
52 Week Low 3290.87
50-Day Moving Average 3424.38
200-Day Moving Average 3373.25

Share Statistics

Avg Vol (3 month) 32.91k
Avg Vol (10 day) 31.2k
Shares Outstanding 5255.56M
Implied Shares Outstanding 6N/A
Float 8257.29M
% Held by Insiders 10.10%
% Held by Institutions 195.79%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 4N/A
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Mar 31, 2024

Profitability

Profit Margin 39.46%
Operating Margin (ttm)45.20%

Management Effectiveness

Return on Assets (ttm)12.82%
Return on Equity (ttm)24.38%

Income Statement

Revenue (ttm)10.18B
Revenue Per Share (ttm)39.49
Quarterly Revenue Growth (yoy)13.30%
Gross Profit (ttm)N/A
EBITDA 4.58B
Net Income Avi to Common (ttm)4.02B
Diluted EPS (ttm)9.48
Quarterly Earnings Growth (yoy)57.10%

Balance Sheet

Total Cash (mrq)10.17B
Total Cash Per Share (mrq)39.42
Total Debt (mrq)721.3M
Total Debt/Equity (mrq)3.89%
Current Ratio (mrq)3.50
Book Value Per Share (mrq)71.80

Cash Flow Statement

Operating Cash Flow (ttm)3.94B
Levered Free Cash Flow (ttm)3.31B